Related Experiment Videos
Japanese experience with dual-action antidepressants
1Department of Mental Health, Kyorin University School of Health Sciences, Hachioji, Tokyo, Japan. tajimao@kyorin-u.ac.jp
International Clinical Psychopharmacology
|October 9, 2002
Summary
Milnacipran, a dual-action antidepressant, shows efficacy and better tolerability than older drugs. It may offer a faster onset of action and benefits for specific mood disorders.
Area of Science:
- Pharmacology
- Neuroscience
- Psychiatry
Background:
- Milnacipran is a novel dual-action antidepressant introduced in Japan.
- It demonstrates comparable efficacy and superior tolerability to imipramine and mianserin in clinical trials.
- Phase IV studies confirm its favorable safety profile.
Purpose of the Study:
- To evaluate the efficacy and tolerability of milnacipran compared to existing antidepressants.
- To investigate the potential for a rapid onset of action.
- To explore milnacipran's utility in treating specific affective disorders.
Main Methods:
- Placebo-controlled clinical trials.
- Open-label phase IV studies.
- Pilot studies for specific affective disorders.
Main Results:
- Milnacipran showed similar efficacy and superior tolerability to imipramine and mianserin.
- Indications suggest a rapid onset of action, with efficacy observed after one week.
- Potential benefits were noted in bipolar disorder, elderly treatment-resistant depression, and post-stroke depression.
Conclusions:
- Milnacipran offers a favorable safety and efficacy profile, potentially surpassing older antidepressants.
- The drug may provide a faster therapeutic response, possibly linked to 5-HT1A receptor desensitization.
- Further controlled studies are warranted to confirm its efficacy in specific affective disorders.